Citigroup Inc. vs TransMedics Group Inc — how do they compare? Citigroup Inc. trades at $136 (market cap $227.75B), while TransMedics Group Inc trades at $89.4 (market cap $3.10B). The key difference: Citigroup Inc. is far larger — about 73.5× TransMedics Group Inc's market cap, and Citigroup Inc. pays a 1.97% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| C | TMDX | |
|---|---|---|
Market Cap | $227.75B | $3.10B |
Sector | Financials | Technology |
52-Week High | $145.67 | $150.42 |
52-Week Low | $92.59 | $61.99 |
Dividend Yield | 1.97% | — |
Enterprise Value | — | $3.49B |
Signals from Pluang's Aura AI — not financial advice
Citigroup (C) trades at $135.22, up 0.17% with bullish technical signals and strong fundamental momentum. The stock shows robust earnings performance with Q1 and Q2 2026 beats, revenue growth to $85.21B in 2025, and improving profit margins. Analyst consensus is strongly bullish with a $154.38 price target, supported by recent strategic hires and digital transformation initiatives.
Outlook remains positive with revenue projected to reach $91.4B in 2026 and net income margin expanding to 19.52%. Key risks include volatile cash flow patterns and high debt levels. The current valuation at 14.63 P/E offers attractive upside potential relative to analyst targets, though investors should monitor execution of the bank's transformation strategy.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.
Read more on C →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →